Identification of high-risk oral leukoplakia (OLK) using combined Raman spectroscopic analysis of brush biopsy and saliva samples: A proof of concept study.

The gold standard method of diagnosis of oral leukoplakia (OLK) is a tissue biopsy followed by histological examination. Raman spectroscopic studies of cytological brush biopsy and saliva samples have previously been shown to differentiate low (no and mild dysplasia) and high risk (moderate and severe dysplasia) OLKs, discriminant models of cellular samples achieving higher specificity, whereas those based on saliva samples achieved higher sensitivity. The current study combines the spectral data sets of cell and saliva samples in an attempt to improve the overall efficiency of the discriminating models.

The impact of elexacaftor/tezacaftor/ivacaftor on cystic fibrosis health-related quality of life and decision-making about daily treatment regimens: a mixed methods exploratory study.

Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has reduced many symptoms of cystic fibrosis (CF).

Objectives: We sought to identify the impact of ETI on both symptoms and treatment decisions among adults with CF.

Design: Participants were enrolled in a cross-sectional study.

Trial Forge Guidance 4: a guideline for reporting the results of randomised Studies Within A Trial (SWATs).

Background: Evidence to support decisions on trial processes is minimal. One way to generate this evidence is to use a Study Within A Trial (SWAT) to test trial processes or explore methodological uncertainties. SWAT evidence relies on replication to ensure sufficient power and broad applicability of findings.

Biological therapies and management of oral mucosal disease.

Biologic drugs are drugs made by living organisms and the term is usually limited to monoclonal antibodies or receptors targeting specific cytokines or cells that have been developed in recent decades. These drugs have had an enormous impact on the management of cancers, including head and neck cancers, and immune-mediated inflammatory conditions, for example, rheumatoid arthritis and inflammatory bowel disease. General dental practitioners will routinely be managing patients who are on these medications for a wide range of systemic conditions.